To demonstrate that TF exerts a tumor immune effect by targeting HRD1 to degrade PD‐L1 in tumors, we first interfered with PD‐L1 in RKO cells and found that Jurkat cells had almost the same ability to kill RKO cells when treated with TF alone, TF+siPD‐L1, or siPD‐L1 alone, which further confirmed that TF enhances T cell killing by reducing PD‐L1 in tumors. The gene discussed is SYVN1; the disease is neoplasm.